Drug intelligence / Profile preview

RK014

Development stage: Preclinical
Lead developer: RevolKa
Modality: Recombinant Proteins and Enzymes

Overview

RK014 is an early-stage protein therapeutic currently under development by RevolKa. The drug is being developed using RevolKa's proprietary evolvability-based protein engineering platform, which integrates artificial intelligence with directed evolution to optimize protein functions. As of early 2024, RevolKa has not publicly disclosed the specific molecular target, mechanism of action, or the primary therapeutic indication for RK014. The program is categorized as being in the 'Working' stage of research and development.

Beyond the preview

Go deeper on RK014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK014.

Explore the full profile